Hu Jin-Yue, Li Guan-Cheng, Wang Wen-Meng, Zhu Jian-Gao, Li Yue-Fei, Zhou Guo-Hua, Sun Qu-Bing
Lab of Tumor Immunobiology, Cancer Research Institute, Xiangya Medical School, Central South University, Hunan Province, China.
World J Gastroenterol. 2002 Dec;8(6):1067-72. doi: 10.3748/wjg.v8.i6.1067.
To evaluate the possibility of the induction of anti-tumor immune response by transfecting the colorectal cancer cells with chemokine MCP-3 gene.
Mouse MCP-3 gene was transduced into mouse colorectal cancer cells CMT93 by using of Liposome. G418-resistant clones were selected and the MCP-3 mRNA expression was detected by RT-PCR. The chemotactic activity of MCP-3 in the cell culture supernatant was detected by Chemotaxis assay. The tumorigenicity of wild type CMT93 and CMT93 gene transfectants were detected by in vivo experiments. The immune cell infiltrations in tumor tissue and tumor metastasis were detected histopathologically.
MCP-3 mRNA expression was detected by RT-PCR in gene-transfected cells (CMT93/MCP-3), but not in control groups. And MCP-3 secreted in the cell culture supernatant possessed chemotatic activity. The results from in vivo experiments showed that the tumorigenicity of CMT93/MCP-3 had not decreased, but the tumors derived from CMT93/MCP-3 cells grew more slowly than those from CMT93 cells (1.021+/-0.253) cm(2) vs (1.769+/-0.371) cm(2), P<0.05) or CMT93/mock cells (1.021+/-0.253) cm(2) vs (1.680 +/-0.643)cm(2), P<0.05). Histophathological results showed few immune cells infiltrating in the tumor tissue derived from the controls. In the tumor tissue derived from CMT93/MCP-3, infiltrating immune cells increased. In addition, no tumor metastasis was found in all mice inoculated with CMT93/MCP-3 tumor cells. But all mice had tumor metastasis in CMT93 controls and 4 in 5 mice had tumor metastasis in CMT93/mock controls.
The results suggested that the transfection of chemokine MCP-3 gene could promote the induction of anti-colorectal cancer immunity, but the tumor growth could not be inhibited completely by merely MCP-3 gene transfection.
评估通过趋化因子MCP-3基因转染结肠癌细胞诱导抗肿瘤免疫反应的可能性。
利用脂质体将小鼠MCP-3基因转导入小鼠结肠癌细胞CMT93。筛选出对G418耐药的克隆,采用逆转录聚合酶链反应(RT-PCR)检测MCP-3 mRNA表达。通过趋化性分析检测细胞培养上清液中MCP-3的趋化活性。通过体内实验检测野生型CMT93和CMT93基因转染细胞的致瘤性。通过组织病理学检测肿瘤组织中的免疫细胞浸润和肿瘤转移情况。
RT-PCR检测发现基因转染细胞(CMT93/MCP-3)中有MCP-3 mRNA表达,而对照组中未检测到。细胞培养上清液中分泌的MCP-3具有趋化活性。体内实验结果显示,CMT93/MCP-3的致瘤性未降低,但CMT93/MCP-3细胞形成的肿瘤生长比CMT93细胞形成的肿瘤更缓慢((1.021±0.253) cm² 对 (1.769±0.371) cm²,P<0.05)或CMT93/空载体细胞形成的肿瘤((1.021±0.253) cm² 对 (1.680±0.643)cm²,P<0.05)。组织病理学结果显示,对照组来源的肿瘤组织中免疫细胞浸润较少。在CMT93/MCP-3来源的肿瘤组织中,浸润的免疫细胞增多。此外,接种CMT93/MCP-3肿瘤细胞的所有小鼠均未发现肿瘤转移。但CMT93对照组的所有小鼠均有肿瘤转移,CMT93/空载体对照组的5只小鼠中有4只发生肿瘤转移。
结果表明,趋化因子MCP-3基因转染可促进抗结肠癌免疫的诱导,但单纯MCP-3基因转染不能完全抑制肿瘤生长。